Anti Hipertensi Pada Kehamilan
Anti Hipertensi Pada Kehamilan
PADA KEHAMILAN
Pembimbing:
dr. Sutiyono, Sp.OG (K)
Oleh:
Sandhya Putri Arisanti, S.Ked
(J510155022)
(J510155045)
(J510155062)
(J510155096)
BAB I
A. Latar Belakang Masalah
Definisi dan rekomendasi pengobatan untuk hipertensi dalam
kehamilan, tidak seperti untuk orang-orang
hipertensi pada
populasi umum. Dalam literatur yang relevan sebagai systolic blood
pressure (SBP) >140 mmHg dan / atau diastolic blood pressure
(DBP) >90 mmHg.
B. Rumusan Masalah
Hipertensi?
Anti
hipertensi
pada
kehamilan
Menjelaskan obat anti hipertensi yang aman untuk ibu hamil dan
menambah khasanah keilmuan pada bidang ilmu penyakit
kandungan dan kebidanan.
Teoritis
Aplikatif
Referat
ini
diharapkan
dapat
meningkatkan kesadaran akan pentingnya
penanganan hipertensi pada ibu hamil.
BAB II
A. DEFINISI
Hipertensi kronis
Preeklampsia-eklampsia
BAB III
A. KESIMPULAN
Metildopa merupakan obat pilihan utama untuk hipertensi kronik parah pada
kehamilan (tekanan diastolik lebih dari 110 mmHg) yang dapat menstabilkan
aliran darah uteroplasenta dan hemodinamik janin.
Metildopa aman bagi ibu dan anak, dimana telah digunakan dalam jangka
waktu yang lama dan belum ada laporan efek samping pada pertumbuhan
dan perkembangan anak.
BAB IV
DAFTAR PUSTAKA
Report of the National High Blood Pressure Education Program Working Group on High Blood
Pressure in Pregnancy. Am J Obstet Gynecol. 2000;183(1):S122.
Homer CS, Brown MA, Mangos G, Davis GK. Non-proteinuricpre-eclampsia: a novel risk indicator in
women with gestationalhypertension. J Hypertens. 2008;26(2):295302.
doi:10.1097/HJH.0b013e3282f1a953.
Pettit F, Brown MA. The management of pre-eclampsia: what wethink we know. Eur J
ObstetGynecolReprod Biol.2012;160(1):612. doi:10.1016/j.ejogrb.2011.09.049.
Trogstad L, Magnus P, Stoltenberg C. Pre-eclampsia: risk factorsand causal models. Best Pract Res
ClinObstetGynaecol.2011;25(3):32942.
James JL, Whitley GS, Cartwright JE. Pre-eclampsia: fittingtogether the placental, immune and
cardiovascular pieces.J Pathol. 2010;221(4):36378. doi:10.1002/path.2719.
Wang A, Rana S, Karumanchi SA. Preeclampsia: the role ofangiogenic factors in its pathogenesis.
Physiology. 2009;24: 14758. doi:10.1152/physiol.00043.2008.
Cetin I, Huppertz B, Burton G, Cuckle H, Gonen R, Lapaire O,et al. Pregenesys pre-eclampsia
markers consensus meeting: whatdo we require from markers, risk assessment and model
systemsto tailor preventive strategies? Placenta. 2011;32(Suppl):S4
16.doi:10.1016/j.placenta.2010.11.022.
Brown CM, Garovic VD. Mechanisms and management ofhypertension in pregnant women.
CurrHypertens Rep.2011;13:33846. doi:10.1007/s11906-011-0214-y.
Jonsdottir LS, Arngrimsson R, Geirsson RT, Sigvaldason H,Sigfusson N. Death rates from ischemic
heart disease in womenwith a history of hypertension in pregnancy. ActaObstetGynecolScand.
1995;74(10):7726.
Smith G, Pell J, Walsh D. Pregnancy complications and maternalrisk of ischaemic heart disease: a
retrospective cohort study of129 290 births. Lancet. 2001;357(9273):20026. doi:10.1016/s01406736(00)05112-6.
Wilson BJ, Watson MS, Prescott GJ, Sunderland S, CampbellDM, Hannaford P, et al. Hypertensive
diseases of pregnancy andrisk of hypertension and stroke in later life: results from cohortstudy.
BMJ. 2003;326(7394):845. doi:10.1136/bmj.326.7394.845.
ACOG. Practice bulletin #33: diagnosis and management ofpreeclampsia and eclampsia. Obstet
Gynecol. 2002;99(1):15967.
Anderson GD, Carr DB. Effect of pregnancy on the pharmacokineticsof antihypertensive drugs.
ClinPharmacokinet. 2009;48(3):15968. doi:10.2165/00003088-200948030-00002.
Cockburn J, Moar VA, Ounsted M, Redman CW. Final report ofstudy on hypertension during
pregnancy: the effects of specifictreatment on the growth and development of the children.
Lancet.1982;1(8273):6479.
Khalil A, Harrington K, Muttukrishna S, Jauniaux E. Effect ofantihypertensive therapy with alphamethyldopa on uterine arteryDoppler in pregnancies with hypertensive disorders.
UltrasoundObstet Gynecol. 2010;35(6):68894. doi:10.1002/uog.7611.
Magee LA. Treating hypertension in women of child-bearing ageand during pregnancy. Drug Saf.
2001;24(6):45774.
Horvath JS, Phippard A, Korda A, Henderson-Smart DJ, Child A,Tiller DJ. Clonidine hydrochloride
a safe and effective antihypertensiveagent in pregnancy. Obstet Gynecol. 1985;66(5):6348.
Magee LA, Cham C, Waterman EJ, Ohlsson A, vonDadelszen P.Hydralazine for treatment of severe
hypertension in pregnancy:meta-analysis. BMJ. 2003;327(7421):95560.
doi:10.1136/bmj.327.7421.955.
Abalos E, Duley L, Steyn DW, Henderson-Smart DJ. Antihypertensivedrug therapy for mild to
moderate hypertension duringpregnancy. Cochrane Database Syst Rev.
2007(1):CD002252.doi:10.1002/14651858.CD002252.pub2.
Lowe SA, Brown MA, Dekker GA, Gatt S, McLintock CK,McMahon LP, et al. Guidelines for the
management of hypertensivedisorders of pregnancy 2008. Aust N Z J
ObstetGynaecol.2009;49(3):2426. doi:10.1111/j.1479-828X.2009.01003.x.
Magee LA, Helewa M, Moutquin JM, von Dadelszen P. HypertensionGuideline Committee, Society of
Obstetricians andGynaecologists of Canada. Treatment of the hypertensive disordersof pregnancy. In:
Diagnosis, evaluation, and management ofthe hypertensive disorders of pregnancy. J ObstetGynaecol
Can.2008;30(3 Suppl 1):S2436.
Magee LA, Schick B, Donnenfeld AE, Sage SR, Conover B,Cook L, et al. The safety of calcium channel
blockers in humanpregnancy: a prospective, multicenter cohort study. Am J ObstetGynecol.
1996;174(3):8238.
Papatsonis DN, Lok CA, Bos JM, Geijn HP, Dekker GA. Calciumchannel blockers in the management of
preterm labor andhypertension in pregnancy. Eur J ObstetGynecolReprod Biol.2001;97(2):12240.
Shoemaker CT, Meyers M. Sodium nitroprusside for control ofsevere hypertensive disease of pregnancy: a
case report anddiscussion of potential toxicity. Am J Obstet Gynecol. 1984;149(2):1713.
Sibai BM, Grossman RA, Grossman HG. Effects of diuretics onplasma volume in pregnancies with long-term
hypertension. Am JObstet Gynecol. 1984;150(7):8315.
Jim B, Sharma S, Kebede T, Acharya A. Hypertension in pregnancy:a comprehensive update. Cardiol Rev.
2010;18(4):17889.doi:10.1097/CRD.0b013e3181c60ca6.
Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, DyerS, Gideon PS, et al. Major congenital
malformations after firsttrimesterexposure to ACE inhibitors. N Engl J Med.2006;354(23):244351.
doi:10.1056/NEJMoa055202.
Bateman BT, Hernandez-Diaz S, Huybrechts KF, Palmsten K,Mogun H, Ecker JL, et al. Patterns of outpatient
antihypertensivemedication use during pregnancy in a Medicaid population.Hypertension. 2012;60(4):913
20. doi:10.1161/HYPERTENSIONAHA.112.197095.
Duley L, Gulmezoglu AM, Henderson-Smart DJ, Chou D.Magnesium sulphate and other anticonvulsants for
women withpre-eclampsia. Cochrane Database Syst Rev.
2010;11:CD000025.doi:10.1002/14651858.CD000025.pub2.
Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplateletagents for preventing pre-eclampsia and its
complications.Cochrane Database Syst Rev. 2007(2):CD004659. doi:10.1002/14651858.CD004659.pub2.
Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, BohmM, et al. 2013 ESH/ESC Guidelines for the
management ofarterial hypertension: the Task Force for the management ofarterial hypertension of the
European Society of Hypertension(ESH) and of the European Society of Cardiology (ESC). J
Hypertens.2013;31(7):1281357. doi:10.1097/01.hjh.0000431740.32696.cc.
Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, MarcouxS, et al. Prevention of preeclampsia and
intrauterine growthrestriction with aspirin started in early pregnancy: a meta-analysis.Obstet Gynecol.
2010;116(2 Pt 1):40214. doi:10.1097/AOG.0b013e3181e9322a.
Roberts JM, Myatt L, Spong CY, Thom EA, Hauth JC, LevenoKJ, et al. Vitamins C and E to prevent
complications of pregnancy-associated hypertension. N Engl J Med. 2010;362(14): 128291.
doi:10.1056/NEJMoa0908056.
Hofmeyr GJ, Lawrie TA, Atallah AN, Duley L. Calcium supplementationduring pregnancy for preventing
hypertensive disordersand related problems. Cochrane Database SystRev.2010(8):CD001059.
doi:10.1002/14651858.CD001059.pub3.
European Society of Gynecology, Association for EuropeanPaediatric C, German Society for Gender
Medicine, Regitz-Zagrosek V, BlomstromLundqvist C, Borghi C, et al. ESCGuidelines on the management of
cardiovascular diseases duringpregnancy: the Task Force on the Management of CardiovascularDiseases
during Pregnancy of the European Society of Cardiology(ESC). Eur Heart J. 2011;32(24):314797.
doi:10.1093/eurheartj/ehr218.
Olsen SF, Osterdal ML, Salvig JD, Weber T, Tabor A, SecherNJ. Duration of pregnancy in relation to fish oil
supplementationand habitual fish intake: a randomised clinical trial withfish oil. Eur J ClinNutr.
2007;61(8):97685. doi:10.1038/sj.ejcn.1602609.
Magee LA, von Dadelszen P, Chan S, Gafni A, Gruslin A, HelewaM et al. the control of hypertension in
pregnancy study pilottrial. BJOG. 2007;114(6):770, e1320. doi:10.1111/j.1471-0528.2007.01315.x.
Wang K, Ahmad S, Cai M, Rennie J, Fujisawa T, Crispi F,et al. Dysregulation of hydrogen sulfide producing
enzymecystathionine gamma-lyase contributes to maternal hypertensionand placental abnormalities in
preeclampsia. Circulation.2013;127(25):251422. doi:10.1161/CIRCULATIONAHA.113.001631.
George EM, Cockrell K, Aranay M, Csongradi E, StecDE,Granger JP. Induction of hemeoxygenase 1 attenuates
placentalischemia-induced hypertension. Hypertension. 2011;57:9418.doi:10.1161/hypertensionaha.111.169755.
Uddin MN, Horvat D, DeMorrow S, Agunanne E, Puschett JB.Marinobufagenin is an upstream modulator of Gadd45a
stresssignaling in preeclampsia. BiochimBiophysActa. 2011;1812(1):4958. doi:10.1016/j.bbadis.2010.09.006.
McGuane J, Conrad K. GPCRs as potential therapeutic targets inpreeclampsia. Drug Discov Today Dis Models.
2012;9(3):e11927. doi:10.1016/j.ddmod.2012.05.001.Drug Treatment of Hypertension in Pregnancy 295
Walsh SK, English FA, Crocker IP, Johns EJ, Kenny LC. Contributionof PARP to endothelial dysfunction and hypertension
ina rat model of pre-eclampsia. Br J Pharmacol. 2012;166(7):210916. doi:10.1111/j.1476-5381.2012.01906.x.
Lowe DT. Nitric oxide dysfunction in the pathophysiology ofpreeclampsia. Nitric Oxide. 2000;4(4):44158.
doi:10.1006/niox.2000.0296.
Motterlini R, Otterbein LE. The therapeutic potential of carbonmonoxide. Nat Rev Drug Discov. 2010;9(9):72843.
doi:10.1038/nrd3228.
Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S,Hansson L, et al. Blood pressure dependent and
independenteffects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet. 2004;363(9426):2049
51. doi:10.1016/S0140-6736(04)16456-8.
Gradman AH, Basile JN, Carter BL, Bakris GL. Combinationtherapy in hypertension. J Am SocHypertens. 2010;4(1):42
50.doi:10.1016/j.jash.2010.02.005.
Martin JN Jr, Thigpen BD, Moore RC, Rose CH, Cushman J,May W. Stroke and severe preeclampsia and eclampsia: a
paradigmshift focusing on systolic blood pressure. Obstet Gynecol.2005;105(2):24654.
doi:10.1097/01.AOG.0000151116.84113.56.
Antenatal Care. Routine care for the healthy pregnant woman.London: National Institute for Health and Clinical
Excellence:Guidance; 2008.
OBrien E, Parati G, Stergiou G, Asmar R, Beilin L, Bilo G, et al.European society of hypertension position paper on
ambulatoryblood pressure monitoring. J Hypertens. 2013;31(9):173168.doi:10.1097/HJH.0b013e328363e964.
Mancia G, De Backer G, Dominiczak A, Cifkova R, FagardR,Germano G, et al. 2007 Guidelines for the Management
ofArterial Hypertension: the Task Force for the Management ofArterial Hypertension of the European Society of
Hypertension(ESH) and of the European Society of Cardiology (ESC). J Hypertens.2007;25(6):110587.
doi:10.1097/HJH.0b013e3281fc975a.
Duley L, Meher S, Jones L. Drugs for treatment of very highblood pressure during pregnancy. Cochrane Database Syst
Rev.2013;7:CD001449. doi:10.1002/14651858.CD001449.pub3.
Moser M, Brown CM, Rose CH, Garovic VD. Hypertension inpregnancy: is it time for a new approach to treatment? J
Hypertens.2012;30(6):1092100. doi:10.1097/HJH.0b013e3283536319